Is Covid largely over or is the biotech sector ripe for more upside? episode artwork

EPISODE · Jan 26, 2022 · 24 MIN

Is Covid largely over or is the biotech sector ripe for more upside?

from In the market for more · host IG Group

Investments in the biotech, pharmaceutical and life science sectors have seen some good returns since COVID struck. While it is true that much of the initial gains have been retraced, Dr Navid Malik, a medically trained specialist who is now a life sciences, pharma and biotech analyst, says there is more to come as the sector prepares for more vaccines to combat new variants, and also brings the illusive COVID pill to the market.  Any opinion, news, research, analysis, or other information does not constitute investment or trading advice.  Follow us on Twitter, Instagram and YouTube

NOW PLAYING

Is Covid largely over or is the biotech sector ripe for more upside?

0:00 24:07

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Frequently Asked Questions

How long is this episode of In the market for more?

This episode is 24 minutes long.

When was this In the market for more episode published?

This episode was published on January 26, 2022.

What is this episode about?

Investments in the biotech, pharmaceutical and life science sectors have seen some good returns since COVID struck. While it is true that much of the initial gains have been retraced, Dr Navid Malik, a medically trained specialist who is now a life...

Can I download this In the market for more episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!